SCHEMBL2261407

SCHEMBL2261407

NC(=O)CSc1nc2ccccc2s1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.77
APEX1 P27695 1/20 0.77
RECQL P46063 1/20 0.77
MAPT P10636 3/20 0.73
ALOX5 P09917 1/20 0.66
CYP1A2 P05177 4/20 0.63
CYP2D6 P10635 3/20 0.63
MAPK1 P28482 3/20 0.63
CYP3A4 P08684 3/20 0.63
CYP2C19 P33261 3/20 0.63
HIF1A Q16665 1/20 0.63
L3MBTL1 Q9Y468 1/20 0.63
ALDH1A1 P00352 7/20 0.63
HPGD P15428 6/20 0.63
NPC1 O15118 2/20 0.63
RAB9A P51151 2/20 0.63
GFER P55789 1/20 0.63
SMN1; SMN2 Q16637 3/20 0.62
HSD17B10 Q99714 3/20 0.62
MEN1 O00255 2/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1286369 0.86 POLB (0.79) POLBAPEX1RECQLMAPTALOX5
SCHEMBL8984918 0.85 POLB (0.76) POLBAPEX1RECQLMAPTALOX5
SCHEMBL5401249 0.84 POLB (0.77) POLBAPEX1RECQLMAPTALOX5
SCHEMBL13629728 0.84 MAPT (1.00) POLBAPEX1RECQLMAPTALOX5
SCHEMBL9375886 0.84 POLB (0.71) POLBAPEX1RECQLMAPTALOX5
SCHEMBL10759553 0.83 POLB (0.75) POLBAPEX1RECQLMAPTALOX5
SCHEMBL10404196 0.82 POLB (0.73) POLBAPEX1RECQLMAPTALOX5
SCHEMBL10404194 0.82 POLB (0.73) POLBAPEX1RECQLMAPTALOX5
SCHEMBL13461102 0.82 POLB (0.83) POLBAPEX1RECQLMAPTALOX5
SCHEMBL10404170 0.81 POLB (0.71) POLBAPEX1RECQLMAPTALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195500-A1 METHODS AND COMPOSITIONS FOR MITIGATING EOSINOPHILIC ESOPHAGITIS BY MODULATING LEVELS AND ACTIVITY OF EOTAXIN-3 CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2011-08-11 US claimed
US-20090233275-A1 EOTAXIN-3 IN EOSINOPHILIC ESOPHAGITIS CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2009-09-17 US claimed
WO-2006083390-A2 EOTAXIN-3 IN EOSINOPHILIC ESOPHAGITIS CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2006-08-10 WO claimed
US-10155985-B2 Evaluation of eosinophilic esophagitis CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2018-12-18 US disclosed
US-20170067111-A1 Evaluation of Eosinophilic Esophagitis CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2017-03-09 US disclosed
US-8030003-B2 Diagnosis of eosinophilic esophagitis based on presence of an elevated level of eotaxin-3 CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2011-10-04 US disclosed
US-20110195500-A1 METHODS AND COMPOSITIONS FOR MITIGATING EOSINOPHILIC ESOPHAGITIS BY MODULATING LEVELS AND ACTIVITY OF EOTAXIN-3 CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2011-08-11 US disclosed
US-20090269774-A1 EVALUATION OF EOSINOPHILIC ESOPHAGITIS CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2009-10-29 US disclosed
US-20090233275-A1 EOTAXIN-3 IN EOSINOPHILIC ESOPHAGITIS CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2009-09-17 US disclosed
CN-101437795-A Piperidine derivatives, process for their preparation, their use as therapeutic agents and pharmaceutical compositions containing them ASTRAZENECA AB (SE) 2009-05-20 CN disclosed
US-20090023733-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them ASTRAZENECA AB (SE) 2009-01-22 US disclosed
EP-1363925-B1 MACROLIDE ANTIBIOTICS GLAXO GROUP LTD (GB) 2006-11-15 EP disclosed
US-20060211636-A1 Macrolide Antibiotics ALIHODZIC SULEJMAN 2006-09-21 US disclosed
WO-2006083390-A2 EOTAXIN-3 IN EOSINOPHILIC ESOPHAGITIS CHILDREN'S HOSPITAL MEDICAL CENTER (US) 2006-08-10 WO disclosed
US-20050215495-A1 Macrolide antibiotics ALIHODZIC SULEJMAN 2005-09-29 US disclosed
US-20040077557-A1 Macrolide antibiotics GLAXO GROUP LIMITED (GB) 2004-04-22 US disclosed
US-4719036-A PAINTS; METAL WORKING CIBA-GEIGY CORPORATION (US) 1988-01-12 US disclosed
US-4329363-A Substituted mercapto acid amides and their use MERCK & CO., INC. (US) 1982-05-11 US disclosed
EP-0006347-A1 Compositions and method for regulating soybean plant growth utilizing substituted benzazolylthioalkanoic acids MONSANTO COMPANY (US) 1980-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215495-A1 Macrolide antibiotics IL1R1, MRPL12, RPS21 POLB 2625/4885APEX1 4284/4885RECQL 1088/4885
US-20090023733-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them CCR3, CCR1, CCR5 POLB 1667/4885APEX1 3375/4885RECQL 4059/4885
US-20060211636-A1 Macrolide Antibiotics IL1R1, MRPL12, RPS21 POLB 2625/4885APEX1 4284/4885RECQL 1088/4885
US-20040077557-A1 Macrolide antibiotics MALT1, MRPL21, IL1R1 POLB 2847/4885APEX1 3848/4885RECQL 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.